Business
Short extension to NICE publication date
Short extension to NICE publication date.
About this update from Genedrive Plc
[{"type":"text","content":"\n\ngenedrive plc\n(\"genedrive\" or the \"Company\")\n \nShort extension to NICE publication date on CYP2C19 test\n \ngenedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, acknowledges, as announced on 3 April 2024, that the UK's National Institute for Health and Care Excellence (\"NICE\") has recommended in draft guidance that CYP2C19 genotyping should be used to guide clopidogrel use after Ischaemic Stroke (\"IS\") or Transient Ischaemic Attack (\"TIA\"), and that the Genedrive® CYP2C19-ID test should be used as the test of choice for point-of-care strategies. \n \nThe final publication was expected by NICE on 10 July 2024, but the Company notes from the NICE website that this has recently been extended to 31 July 2024. Further details can be found at: https://www.nice.org.uk/guidance/indevelopment/gid-dg10054/documents.\n \nFor further details please contact:\n \n\n\n\n\ngenedrive plc\n\n\n+44 (0)161 989 0245\n\n\n\n\nJames Cheek: CEO / Russ Shaw: CFO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt LLP (Nominated Adviser and Broker)\n\n\n+44 (0)20 7418 8900\n\n\n\n\nJames Steel / Patrick Birkholm\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Ltd (Media & Investor Relations)\n\n\n+44 (0)20 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\n+44 (0)7876 741 001\n\n\n\n\n \nAbout genedrive plc (http://www.genedriveplc.com). genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of point-of-care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS...